Key Points Viking Therapeutics' recent clinical trial results for its leading weight loss candidate were excellent. But Eli Lilly, the leader in this area, has a robust pipeline of its own and has little to fear from its smaller rival. Viking Therapeutics and Eli Lilly offer two very different investment theses. 10 stocks we like better than Viking Therapeutics › Eli Lilly (NYSE: LLY) is currently the leader in the weight loss market. However, the company's success is attracting increasingly more competition, and we should see several anti-obesity medicine launches over the next few years. Viking Therapeutics (NASDAQ: VKTX) is one of those drugmakers that might eventually challenge Eli Lilly.
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.